Skip to main content
UTHR logo

UTHR

United Therapeutics Corporation

$554.67

0.79%

Trade Ideas Performance

Latest Closed Trade Idea

$554.67

0.79%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

1

Social

55

About

Events of United Therapeutics Corporation (UTHR)

Over the past six months, United Therapeutics reported record third-quarter 2026 revenue of $833 million, driven by record Tyvaso sales of $504 million, reflecting stronger demand and increased dosing. The company announced a delay in a regulatory submission for its soft mist inhaler to 2027 following an FDA meeting. Other events include an additional $2 billion share repurchase authorization, FDA clearance for a clinical trial for Treprostinil-Iloprost SMI in PAH, and the buydown of a Ralinepag royalty. A court decision upheld UTHR's intellectual property, leading to a settlement with Liquidia regarding YUTREPIA. Insider trading involved the CEO's family trusts exercising options and selling shares. The stock reached an all-time high of $609.99 on October 29, 2026, and was trading at $608.49 on November 5, 2026, suggesting it was 40.2% overvalued compared to its GF Value™ of $433.95. UTHR's share price underperformed the S&P500 Index by -2.95% over the past six months.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)